ABSTRACT
Chemotherapy (with Ephraim S Casper) Control of the primary site can be achieved in the majority of cases of extremity soft tissue sarcoma, but nearly half of all patients ultimately experience distant metastases or progressive localized disease. The role of systemic chemotherapy as part of primary therapy for patients with high-risk soft tissue sarcoma is under active investigation. As is the case for patients with other advanced solid tumors, systemic chemotherapy offers patients with advanced soft tissue sarcoma the possibility of tumor control and palliation of symptoms. Nonetheless, therapeutic responses are seen in fewer than 50% of patients, and durable complete regressions are rare.
